bioAffinity Technologies partners with Pictor on asthma and COPD diagnostics
The San Antonio biotech will combine its flow cytometry work with Pictor's proteomic platform to build tests aimed at guiding personalized asthma and COPD treatment.
bioAffinity Technologies, Inc. announced on July 22, 2026 a collaboration with Pictor, Inc. to support development and commercialization of next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease.1
Under the agreement, bioAffinity's expertise in flow cytometry will be integrated with Pictor's targeted proteomic analysis platform to look at immune cell populations and cytokine profiles linked to airway inflammation.1 CEO Maria Zannes said Pictor's targeted proteomic platform has the ability to lower operating costs compared with traditional single-analyte testing by improving laboratory efficiency and reducing testing complexity.1
On intellectual property, bioAffinity will own the IP tied to any tests emerging from the collaboration, while Pictor retains its existing intellectual property and owns new inventions related to its proteomic platform technology.1
The new tests build on the same sputum-analysis approach used in CyPath Lung, the Company's commercially available noninvasive test that helps physicians assess the likelihood that a pulmonary nodule is malignant.1 The company said it anticipates the new tests will initially be offered as Laboratory Developed Tests under the Clinical Laboratory Improvement Amendments.1
Chief Medical Officer Gordon Downie said by measuring immune cell populations using flow cytometry and integrating Pictor's cytokine profiling platform into its test protocol, the new diagnostics are designed to give physicians a more complete understanding of the biological processes driving airway inflammation in real time.1
On market size, the companies cited a global asthma and COPD therapeutics market valued at approximately $92 billion in 2024, projected to grow past $108 billion by 2026 and $155 billion by 2030, tied to rising use of targeted therapies and biologics.1 They also noted CDC data showing asthma and COPD affect more than 40 million Americans and over 650 million people worldwide.1
Pictor CEO Jamie Platt, who joined bioAffinity's Board of Directors in 2023,1 said the partnership aims to move diagnostics toward understanding the underlying biology of each patient's condition, leading to more effective treatments.1 The filing listed no financial terms for the collaboration.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.